NCT07364734 Epidemiological Characteristics and Efficacy Evaluation of Difficult-To-Treat Crohn's Disease
| NCT ID | NCT07364734 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Xiang Gao |
| Condition | Crohn Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,400 participants |
| Start Date | 2025-11-01 |
| Primary Completion | 2027-11-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Difficult to treat Crohn's disease (DTT-CD) was defined by the International Organization for the Study of Inflammatory Bowel Diseases (IOIBD) in 2023, which refers to CD patients with poor response to drug treatment and poor prognosis. Foreign epidemiological studies have shown that DTT-CD accounts for 24.8% of all CD patients, and most of them are patients with advanced treatment failure according to more than two different mechanisms. Our previous retrospective data suggested that compared with foreign DTT-CD patients, there was no significant difference in the proportion of patients with advanced treatment failure due to more than two different mechanisms, but the proportion of patients with recurrence after two intestinal resection and complex anal fistula was increased. Therefore, this project aims to determine the current prevalence and epidemiological status of DTT-CD in China; To clarify the difference in efficacy and prognosis between DTT-CD patients and non DTT-CD patients using advanced treatment (including biological agents and small molecule drugs); Objective to evaluate the incidence and risk factors of non DTT-CD patients progressing to DTT-CD within 1 year. To further verify whether the domestic DTT-CD population is significantly different from the foreign population, and provide theoretical support for the selection of subsequent treatment options.
Eligibility Criteria
Inclusion Criteria: * The diagnosis of Crohn's disease was confirmed; * Patients aged 18-65; * Informed consent was obtained voluntarily. Exclusion Criteria: * The diagnosis of CD was unclear; * The clinical baseline data were missing seriously; * Patients currently enrolled in clinical trials or receiving experimental drugs; * Other contraindications to biologics or small molecule drugs (including active infection, pregnancy, etc.); * Patients with short bowel syndrome; * Patients with a small bowel or colostomy.